Given that the immunogenically silent KRAS G12D mutation is pathognomonic of pancreatic cancer, our findings may help explain the lack of efficacy of treatments such as checkpoint inhibitors in pancreatic cancer (29) and the lack of immunoediting observed in our analysis, as these tumors are driven largely by an immunogenically silent mutation. Here, KRAS is linked to pancreatic neoplasm.